Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Mar 20, 2025 · 10-K · 79 days after period end · 0001641172-25-000070
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 |
| Net Income | -$2.73M | -$2.40M | -$13.01M | -$3.18M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Dec 31, 2024 · filed Mar 20, 2025 · 79 d after period end
